Lucid Diagnostics closes $15 million preferred stock private placement
LUCD•Lucid Diagnostics closed a $15 million private placement of Series C Convertible Preferred Stock on October 21, 2026. The shares were sold for $1,000 each and convert into common stock at $0.3519 per share.
1. Placement details
Lucid Diagnostics said it closed the private placement on October 21, 2026. Investors included existing long-term shareholders holding a majority of the company's 12% senior secured convertible notes due 2029. Net proceeds will support near-term commercial operations, working capital and general corporate purposes.
